Psychotic Disorders Clinical Trial
Official title:
Outcome of Stage-specific Early Intervention for Psychosis in Hong Kong: A Randomized Controlled Study
| NCT number | NCT00919620 |
| Other study ID # | jcep-rct |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | June 2009 |
| Est. completion date | December 2015 |
| Verified date | November 2020 |
| Source | The University of Hong Kong |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
One of the commonly adopted strategies in improving outcome in psychotic disorders is by focused, specific and intensive intervention in the initial few years of the disorder. However the effects of intervention and the optimal duration of intervention have seldom been examined in randomized studies. This study uses a randomized controlled study design to investigate the effectiveness of stage-specific case-management in improving outcome of first episode psychotic disorders. It also addresses whether two years of case-management is less effective than four years of case-management over a four year period. A total of 360 subjects, who aged 25 above, and diagnosed with first episode psychotic disorders, will be and randomized into 3 groups: (1) standard care alone without case management, (2) two-year case management, (3) four-year case management. All groups will receive usual standard care treatment. This four-year follow-up study will assess symptoms, functioning, quality of life as well as health economics data.
| Status | Completed |
| Enrollment | 360 |
| Est. completion date | December 2015 |
| Est. primary completion date | December 2015 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 26 Years to 55 Years |
| Eligibility | Inclusion Criteria: - DSM-IV diagnosis of schizophrenia, schizoaffective disorder, schizophreniform psychosis, brief psychosis, psychosis nos or delusional disorder - Cantonese-speaking Chinese - Ability to understand the nature of the study and sign informed consent - Capacity to participate in cognitive testing Exclusion Criteria: - Organic Brain disorder - Known history of intellectual disability |
| Country | Name | City | State |
|---|---|---|---|
| China | The University of Hong Kong | Hong Kong |
| Lead Sponsor | Collaborator |
|---|---|
| The University of Hong Kong | Castle Peak Hospital, Kowloon Hospital, Hong Kong, Kwai Chung Hospital, Hong Kong, North District Hospital, Hong Kong, Queen Elizabeth Hospital, Hong Kong, Queen Mary Hospital, Hong Kong, Shatin Hospital, Tai Po Hospital, United Christian Hospital |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Functioning (social and occupational) | baseline, 6-month, 12-month, 24-month, 36-month, 48-month | ||
| Secondary | Psychotic symptoms | Psychotic symptoms will be assessed using the Positive and Negative Syndrome Scale (PANSS) | baseline, 6-month, 12-month, 24-month, 36-month, 48-month | |
| Secondary | Psychotic symptoms | Psychotic symptoms will be assessed using Scale for the Assessment of Positive Symptoms (SAPS) | baseline, 6-month, 12-month, 24-month, 36-month, 48-month | |
| Secondary | Psychotic symptoms | Psychotic symptoms will be assessed using Scale for the Assessment of Negative Symptoms (SANS). | baseline, 6-month, 12-month, 24-month, 36-month, 48-month | |
| Secondary | Depressive symptoms | Depressive symptoms will be assessed using the Calgary Depression Scale for Schizophrenia (CDSS). | baseline, 12-month, 24-month, 36-month, 48-month | |
| Secondary | Neurocognitive functioning | A battery of neurocognitive tests will be conducted, including Handedness, Trail Making, Wisconsin Card Sorting Test, Semantic Verbal Fluency, Logical Verbal Memory, Visual Patterns Test, Letter Number Span, Monotone Counting, and Soft Neurological Signs. | baseline, 12-month, 24-month, 36-month, 48-month | |
| Secondary | Health economics | baseline, 6-month, 12-month, 24-month, 36-month, 48-month |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
| Terminated |
NCT03230097 -
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
|
Phase 2 | |
| Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
| Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
| Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
| Recruiting |
NCT02874573 -
Tocilizumab in Schizophrenia
|
Phase 1 | |
| Terminated |
NCT02584114 -
Brain Effects of Memory Training in Early Psychosis
|
N/A | |
| Completed |
NCT02906553 -
The Role of Nitric Oxide in Cognition in Schizophrenia
|
N/A | |
| Terminated |
NCT02841956 -
Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement
|
N/A | |
| Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
| Completed |
NCT01981356 -
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
|
Phase 0 | |
| Recruiting |
NCT02848469 -
Irish Omega-3 Study
|
Phase 2 | |
| Recruiting |
NCT02009969 -
Serial Comparisons of Abdominal and Neurological MRI Scans
|
N/A | |
| Completed |
NCT02648321 -
Motivational Intervention for Physical Activity in Psychosis
|
N/A | |
| Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
| Completed |
NCT00484302 -
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
|
N/A | |
| Completed |
NCT00844922 -
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
|
Phase 2 | |
| Completed |
NCT00455234 -
Rapid Tranquillization Trial: TREC-India II
|
Phase 3 | |
| Completed |
NCT00130923 -
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
|
Phase 4 | |
| Completed |
NCT00226278 -
Safety Study of ORG 34517 for Major Depression With Psychotic Features
|
Phase 2 |